Impact News +++ Soleno gains as Betaville cites buyout interest (SeekingAlpha) +++ SOLENO Aktie +3,57%

REMEGEN Aktie

>REMEGEN Aktienkurs

7.05 EUR +14.6% (Tradegate)

Ask: 7.05 EUR / 1246 Stück

Bid: 6.85 EUR / 1291 Stück

Tagesumsatz: 5591 Stück

Realtime Kurs von 8 bis 22 Uhr!

REMEGEN Aktie über LYNX handeln

Intraday

1 Jahr

>REMEGEN Performance

1 Woche: +0,4%

1 Monat: +5,7%

3 Monate: +153,2%

6 Monate: +214,1%

1 Jahr: +88,1%

laufendes Jahr: +242,9%

>REMEGEN Aktie

Name:

REMEGEN CO. LTD YC 1

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

CNE1000048G6 / A2QGM4

Symbol/ Ticker:

REG (Frankfurt)

Kürzel:

FRA:REG, ETR:REG, REG:GR

Index:

Webseite:

http://www.remegen.com/

Marktkapitalisierung:

4380 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

74.42 / -

KUV/ KBV/ PEG:

16.26 / 14.68 / -

Gewinnm./ Eigenkapitalr.:

- / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

REMEGEN

Letzte Datenerhebung:

24.06.25

>REMEGEN Eigentümer

Aktien: -

f.h. Aktien: -

Insider Eigner: -

Instit. Eigner: -

Leerverk. Aktien: -

>REMEGEN Peer Group

3SBIO

ASYMCHEM

CHINA SHINEWAY

CK LIFE

MODERN DENTAL

PHARMARON

SHANGHAI HAOHAI

SHANDONG WEIGAO

SINOVAC

YIDU TECH

>REMEGEN Chart & Kurs - Tradegate

>REMEGEN News

17.06.25 - 17:18	RemeGen′s Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis (PR Newswire)
	YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of......

16.06.25 - 05:45	Research: UBS Downgrades REMEGEN to Neutral, Raises TP to HKD63.8 (AAStocks)
	REMEGEN (09995.HK)'s stock price has already snowballed by three times YTD, surpassing the industry's 64% increase, primarily due to progress in its pipeline products and the HKD796 million share placement that alleviated the group's financial strain, according to a report issued by UBS.From a 12-month perspective, U......

27.05.25 - 10:33	RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China (PR Newswire)
	YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of adult patients with anti-acetylcholine......

23.05.25 - 05:00	REMEGEN Continues Rally, Hitting 2-Yr High w/ ~5% Surge; Nomura Lifts TP on Shr Placement Aiming to Raise ~HKD800M (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 10:27	Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS (PR Newswire)
	YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug......

09.04.25 - 04:09	Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis (PR Newswire)
	YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented......

08.01.25 - 11:33	Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma (PR Newswire)
	YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with......

23.12.24 - 03:45	Research: CMSI: Top Picks HANSOH PHARMA/ REMEGEN for CN Innovative Pharma Sector (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

23.12.24 - 03:15	Research: CMSI Rates H-shrs at Cautiously Recommend on 1Q25 Strategy Outlook (AAStocks)
	CMSI's 1Q25 top picks are Amazon.com (AMZN.US), Doordash (DASH.US), Netflix (NFLX.US), MEITUAN-W (03690.HK), TENCENT (00700.HK), Tencent Music Entertainment Group (TME.US), HANSOH PHARMA (03692.HK), 3SBIO (01530.HK), REMEGEN (09995.HK), Alnylam Pharmaceuticals (ALNY.US), Thermo Fisher Scientific (TMO.US), GIANT BIOGENE (0236......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram